Fortifying for a STRONGER FUTURE

Read More

Quantitative highlights for the year

953.2 Crores

Total Revenue

144.3 Crores

EBITDA

63.5 Crores

Profit after Tax

About Neuland

Established in 1984, Neuland Laboratories is a leading manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solutions provider for the pharmaceutical industry for chemistry-related services.

Read More

FAST FACTS

38+

years of experience

100+

APIs across 10 therapeutic areas

80+

countries served

907 kL

API manufacturing capacity

916+

DMFs filed worldwide

75%

revenue from exports

62

active US DMFs

1,521

Employees

Executive Chairman’s Message

At Neuland, we are very proud of our quality and regulatory track record. Understanding that quality is core to our business and future success, the necessary investments continue to be made in strengthening our quality processes. This includes investment in digitisation and automation.

Dr. Davuluri Rama Mohan Rao Executive Chairman
Read More

In conversation with Vice Chairman and CEO

As we look at FY23, we will continue to see challenges on supply chain in terms of both availability & cost given the uncertain geopolitical situation. Our priority is to make the business stronger with focus on understanding the constant evolving customer needs better.

Sucheth Davuluri Vice Chairman and CEO
Read More

Message from Vice Chairman & Managing Director

The FY 2021-22 continued to be testing for the global pharmaceutical industry. This was largely due to pandemic-induced disruptions on the operational, supply chain, demand and pricing side. While pharmaceutical manufacturers are on the recovery path, they continue to face considerable challenges.

Saharsh Davuluri Vice Chairman & Managing Director
Read More

Financial Highlights

Value Creation at Neuland

OUR APPROACH TO VALUE CREATION

Our Strategic Priorities

The roadmap for business fortification and future readiness

Neuland Labs for over 38 years has been a trusted API development and manufacturing partner to leading Pharma and biotech companies globally.
Read More

Operational Highlights

Fortifying our capabilities

Several initiatives completed during the year have enhanced our agility, resilience and ability to create sustainable long- term value. We continue to work towards fortifying our capabilities as outlined under our strategic priorities.
Read More